Panbela Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flynpovi (eflornithine/sulindac) / Panbela Therap
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
ivospemin (SBP-101) / Panbela Therap
2021-005790-60: Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combination with nab-paclitaxel and gemcitabine Estudio para comparar la supervivencia general (SG) entre pacientes que reciben SBP-101 y aquellos que no reciben SBP-101 (es decir, placebo) en combinación con nab-paclitaxel y gemcitabina.

Not yet recruiting
2/3
600
Europe
SBP-101, SBP-101, Solution for injection
Panbela Therapeutics, Inc, Panbela Therapeutics, Panbela Therapeutics, Inc
Metastatic Pancreatic Ductal Adenocarcinoma Adenocarcinoma ductal de páncreas, Pancreatic Cancer Cáncer de páncreas, Diseases [C] - Cancer [C04]
 
 
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flynpovi (eflornithine/sulindac) / Panbela Therap
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
ivospemin (SBP-101) / Panbela Therap
2021-005790-60: Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combination with nab-paclitaxel and gemcitabine Estudio para comparar la supervivencia general (SG) entre pacientes que reciben SBP-101 y aquellos que no reciben SBP-101 (es decir, placebo) en combinación con nab-paclitaxel y gemcitabina.

Not yet recruiting
2/3
600
Europe
SBP-101, SBP-101, Solution for injection
Panbela Therapeutics, Inc, Panbela Therapeutics, Panbela Therapeutics, Inc
Metastatic Pancreatic Ductal Adenocarcinoma Adenocarcinoma ductal de páncreas, Pancreatic Cancer Cáncer de páncreas, Diseases [C] - Cancer [C04]
 
 
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27

Download Options